Literature DB >> 6968267

Immunoglobulin C-gene expression. I. The commitment to IgG subclass of secretory cells is determined by the quality of the nonspecific stimuli.

C Martinez-Alonso, A Coutinho, A A Augustin.   

Abstract

Polyclonal stimulation of normal splenic B lymphocytes with either lipopolysaccharide (LPS) or helper T lymphocytes specific for B cell surface antigens results in the selective expression of IgG subclasses by the secretory cells: in addition to IgM-secreting plaque-forming cells (PFC), thymus-independent stimulation leads to the development of IgG2 and IgG3 PFC, while helper cell-dependent activation leads to IgG1 and IgG2 PFC. This cannot be solely explained by selective stimulation of distinct B cell subpopulations, because purified LPS-reactive blasts if restimulated by helper cells switch to IgG1 while if maintained with LPS switch to IgG3. The simultaneous stimulation of splenic B cells with LPS and helper cells results in additive IgM and IgG2 responses, but in the selective suppression of IgG3 PFC with a concomitant synergic enhancement of IgG1 responses. These results are interpreted to indicate that the expression of IgG C genes in proliferating B lymphocytes is directed by the quality of nonspecific stimuli.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968267     DOI: 10.1002/eji.1830100908

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

1.  Isotype commitment of B cells and dissemination of the primed state after mucosal stimulation with Mycoplasma pulmonis.

Authors:  F V Rose; J J Cebra
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

2.  T-cell regulation of IgG subclass expression by mitogen-induced plasma cells: soluble factors versus the T cells.

Authors:  M Mayumi; T Kuritani; M D Cooper
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

3.  IgG subclass distribution of autoantibodies to DNA and to nuclear ribonucleoproteins in autoimmune diseases.

Authors:  M Zouali; R Jefferis; A Eyquem
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

4.  Interaction of Brucella abortus lipopolysaccharide with major histocompatibility complex class II molecules in B lymphocytes.

Authors:  C Forestier; E Moreno; S Méresse; A Phalipon; D Olive; P Sansonetti; J P Gorvel
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

5.  Frequencies of background cytoplasmic Ig-containing cells in various lymphoid organs of athymic and euthymic mice as a function of age and immune status.

Authors:  A Van Oudenaren; J J Haaijman; R Benner
Journal:  Immunology       Date:  1984-04       Impact factor: 7.397

6.  Serum IgG subclass deficiency in ataxia-telangiectasia.

Authors:  P Aucouturier; C Bremard-Oury; C Griscelli; M Berthier; J L Preud'homme
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

7.  Immunoglobulin G (IgG) and IgA subclass pattern of human antibodies to Shigella flexneri and Salmonella serogroup B and D lipopolysaccharide O antigens.

Authors:  M A Persson; E Ekwall; L Hammarström; A A Lindberg; C I Smith
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

8.  Alteration of the immunoglobulin G subclass responses in mice to lipopolysaccharide: effects of nonbacterial proteins and bacterial membrane phospholipids or outer membrane proteins of Proteus mirabilis.

Authors:  H Karch; J Gmeiner; K Nixdorff
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  The induction of immune complex deposits in mice by peroral and parenteral administration of mercuric chloride: strain dependent susceptibility.

Authors:  P Hultman; S Eneström
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

10.  Serum immunoglobulin G subclass dysbalances in the lymphadenopathy syndrome and acquired immune deficiency syndrome.

Authors:  P Aucouturier; L J Couderc; D Gouet; F Danon; J Gombert; S Matheron; A G Saimot; J P Clauvel; J L Preud'homme
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.